DalCor401

DalCor401 متتبع الأعراض اليومي

Application in support of clinical trials to determine safety of therapeutic intervention for use in humans. eDiary collects signs and symptoms of reactions for 28 days after the treatment and reports data to study investigators. Study participants will receive notification reminders to complete their daily eDiary in accordance with IRB approved schedule. Access to participate in this study requires informed consent by medical personnel. Only after consenting will participants receive an invitation to complete eDiaries. snapIoT and its platforms are HIPAA, California Privacy Rights Act, and GDPR compliant.